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Summary
Paroxysmal extreme pain disorder (PEPD), previously
known as familial rectal pain (FRP, or OMIM 167400),
is an inherited condition characterized by paroxysms
of rectal, ocular, or submandibular pain with flushing.
A genome-wide linkage search followed by mutational
analysis of the candidate gene SCN9A, which encodes
hNav1.7, identified eight missense mutations in 11
families and 2 sporadic cases. Functional analysis
in vitro of three of these mutant Nav1.7 channels re-
vealed a reduction in fast inactivation, leading to per-
sistent sodium current. Other mutations in SCN9A as-
sociated with more negative activation thresholds are
known to cause primary erythermalgia (PE). Carbama-
zepine, a drug that is effective in PEPD, but not PE,
showed selective block of persistent current associ-
ated with PEPD mutants, but did not affect the nega-
tive activation threshold of a PE mutant. PEPD and
PE are allelic variants with distinct underlying bio-
physical mechanisms and represent a separate class
of peripheral neuronal sodium channelopathy.
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Inherited disorders of ion channels are now known to ac-
count for a wide spectrum of human diseases character-
ized by paroxysmal dysfunction of excitable tissues. Un-
derstanding the molecular basis of these disorders has
provided remarkable insights into normal physiological
mechanisms (Ashcroft, 2000; Meisler and Kearney,
2005). The first such channelopathy to be described,
hyperkalemic periodic paralysis, is caused by defects
in the voltage-gated sodium channel of skeletal muscle
Nav1.4 (Ptacek et al., 1991; Rojas et al., 1991). Since this
description, mutations in sodium channels have also
been shown to cause epilepsy and inherited disorders
of cardiac rhythm.
Here we describe a study of the molecular basis of
Paroxysmal extreme pain disorder (PEPD), previously
known as familial rectal pain (Fertleman and Ferrie,
2006), an autosomal dominant paroxysmal disorder of
pain and autonomic dysfunction first identified by Hay-
den and Grossman (1959). Several further families
have since been described (Mann and Cree, 1972; Schu-
bert and Cracco, 1992), and there is evidence that this
condition may be underdiagnosed (Elmslie et al.,
1996). The distinctive features of PEPD are paroxysmal
episodes of burning pain in the rectal, ocular, and man-
dibular areas accompanied by autonomic manifesta-
tions such as skin flushing. The anti-epilepsy drug
carbamazepine is effective in many patients.
A genome-wide linkage search mapped the PEPD
gene to a region of chromosome 2 encompassing
SCN9A, which encodes the Nav1.7 voltage-gated so-
dium channel. The expression pattern and function of
this channel rendered SCN9A an excellent functional
and positional candidate. Additionally, mutations in
this channel were shown to underlie primary erythermal-
gia (PE) (Drenth et al., 2005; Yang et al., 2004), a disease
associated with episodic burning pain, flushing of the
extremities, inflammation, and swelling. Identification
of a distinct repertoire of SCN9A mutations in PEPD, to-
gether with detailed functional analysis, suggest that
these two disorders are allelic variants that are not
only clinically but also mechanistically distinct, and
that differences in the effect of the mutations on sodium
channel activity account for the clear differences in the
clinical phenotypes and in their differential responses
to sodium channel-blocking drugs.
Results
Genetic Mapping of PEPD
We conducted a genome-wide linkage search in one
large pedigree with PEPD, family 7 (Figure 1). We geno-
typed DNA from 13 affected and 13 unaffected family
members using 455 microsatellite markers. The marker
D2S2330 on chromosome 2q gave a LOD score of 4.99
at q = 0. Haplotype analysis (Figure 1) identified critical
recombinants at D2S142 and D2S335, defining a 16
cM critical region containing a cluster of sodium channel
genes. One of these, SCN9A (Klugbauer et al., 1995;
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768Figure 1. Familial Rectal Pain Maps to Chromosome 2q
Pedigree of family 7 showing haplotype of seven markers spanning a region of 26 cM on chromosome 2q24.1 to 32.1. DNA from all individuals
was available apart from individuals I:1 and I:2. The disease chromosome is shown boxed and is inherited by all affected members of the
pedigree. Two critical recombination events in individuals IV:2 and IV:3 delineate a critical region betweenD2S142 andD2S335 of approximately
16 cM. Pedigrees of other families with SCN9A mutations are available (see the Supplemental Data online).Toledo-Aral et al., 1997), encoding the hNav1.7 voltage-
gated sodium channel a-subunit, is expressed only in
the peripheral nervous system, in both sympathetic neu-
rons and the sensory neurons of the dorsal root ganglion
(DRG) (Sangameswaran et al., 1997). Nav1.7 mediates
a tetrodotoxin (TTX) -sensitive, fast-inactivating current
and has a role in acute and inflammatory pain (Nassar
et al., 2004). We therefore investigated SCN9A as a
positional and functional candidate.
Mutational Analysis of SCN9A
We designed intronic primers flanking the 26 exons of
SCN9A to amplify genomic DNA from the probands of
family 7 (individual IV:4, Figure 1), ten additional pedi-
grees (in family 15, only DNA from the proband’s affected
father was available), and two sporadic cases (families
8 and 9). We found a total of eight missense mutations
in 8/13 families (Figure 2A) (See the Supplemental Data
online for additional pedigrees and electropherograms).
All patients are heterozygous for the respective muta-
tions that cosegregated with the disorder in all affected
members from whom DNA was available. In family 12,
the proband is a compound heterozygote, having in-
herited R996C from his affected father, but also having
a de novo mutation (V1298D). This individual is more
severely affected than his father, indicating that R996Cmay represent a subtle mutation. Family 4, in which
R996C is the only mutation, also appears to have a less
severe phenotype not requiring medication.
None of these mutations were present in 192 ethni-
cally matched control chromosomes (data not shown).
All represent nonconservative amino acid changes likely
to have an effect on channel function. Moreover, 7/8
mutations alter amino acids that are conserved across
other human voltage-gated sodium channel a-subunits
as well as those from other species (Figure 2B). Two
mutations (I1461T, F1462V) occur within the highly con-
served IFM amino acid motif in the linker region between
domains III and IV (Figure 2Biii). Site-directed mutagen-
esis studies show that this motif forms the inactivation
gate and plays a pivotal role in fast inactivation (West
et al., 1992; Kellenberger et al., 1997). The T1464I muta-
tion changes a completely conserved threonine residue
immediately adjacent to the IFM domain (Figure 2Biii),
and substitutions at this residue have also previously
been shown to disrupt inactivation by substantially al-
tering the stability of the inactivated state (Kellenberger
et al., 1997). The residues V1298 and V1299 are also
completely conserved (Figure 2Bii) and occur in the
loop between domain III S4-S5, believed to interact
with the domain III-IV inactivation motif (Smith and
Goldin, 1997). The effect of mutations in the S4-S5 linker
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(A) Diagram summarizing the nature and position of eight mutations within Nav1.7. Text colors: black, R996C mutation (families 4 and 12); purple,
V1298F (family 15); pink, V1298D (proband only, family 12); brown, V1299F (family 11); red, I1461T (family 1); orange, F1462V (sporadic case,
family 9); blue, T1464I (family 7); green, M1627K (sporadic case, family 8).
(B) Sodium channel amino acid alignments. The human Nav1.7 sodium channel (hNav1.7) amino acid sequence for the four distinct regions
surrounding the eight PEPD missense mutations is compared with other human sodium channels (hNav1.1–1.9); mouse and rat Nav1.7, and
ancestral sodium channels from fruit fly and jellyfish. (Bi) Lack of conservation of the arginine residue at position 996. By contrast the other seven
mutations alter highly conserved amino acids. (Bii) Complete conservation of valine residues at positions 1298 and 1299. (Biii) High degree of
conservation of the IFM amino acid motif, which forms the inactivation gate and includes the residues I1461 and F1462, and of the adjacent
threonine at position 1464. (Biv) Conservation of methionine at position 1627. The colored triangles indicating the positions of the mutated
residues correspond to the colors used in (A) above.in domain IV has previously been investigated in brain,
heart, and skeletal muscle (McPhee et al., 1998). The
M1627K mutation alters a conserved methionine residue
(Figure 2Biv) that may form part of the inactivation gate
receptor, as previous mutagenesis studies in heart
(Nav1.5) and skeletal muscle (Nav1.4) channels suggest
a role in fast inactivation (Filatov et al., 1998; Lerche
et al., 1997; McPhee et al., 1998; Tang et al., 1996). In
contrast, the arginine at position 996 is not conserved
(Figure 2Bi), although the substitution by cysteine is
not a conservative one and may have a subtle effect
on channel function. This would be consistent with the
less severe nature of the phenotype in family 4 and in
the father in family 12.
Functional Analysis of Three PEPD Mutations
The highly conserved nature of seven of the eight amino
acids mutated in these patients supports a causative role
in the disorder, and their location makes it likely that
channel inactivation would be affected. Therefore, we in-
vestigated the electrophysiological properties of three of
these mutations (I1461T, T1464I, M1627K) using cDNA
constructs of hNav1.7 transfected into HEK293 cells (Fig-
ure 3). Wild-type hNaV1.7 expressed in HEK293 cells
exhibits normal inactivation (Figures 3A–3C). All three
mutant channels exhibited altered inactivation (Figures3D–3F) with associated persistent currents, which were
maintained for more than several hundred milliseconds
in the two inactivation gate mutants (Figures 3D and
3E). There is a depolarizing (rightward) shift in steady-
state inactivation (hN) curves for all three mutants (Fig-
ures 3G–3I) and inactivation is incomplete for I1461T
and T1464I. For M1627K, the greater shift and reduction
in voltage-dependence would widen the range of poten-
tials over which ‘‘window current’’ (activation-inactiva-
tion gating overlap) could operate.
We further investigated the properties of T1464I and
the in vitro effects of carbamazepine, as symptoms in
patients with this mutation are effectively controlled
using this drug. There was a depolarizing shift in the volt-
age-dependence of activation in this mutant (6.8 mV
compared with wild-type, Figure 3C). The average inac-
tivation time constant (th) was less voltage-dependent
and the kinetics of this partial inactivation were rapid
(see the Supplemental Data available with this article
online). The reduced sensitivity of inactivation rate to
membrane potential is seen in other sodium channels
with mutations in the domain III-IV linker (Cannon, 2000).
In response to long depolarizing steps, the T1464I
persistent current was maintained (Figure 4A). In the
presence of carbamazepine, this current was reduced
in a concentration-dependent manner (Figures 4A–4C,
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(A) Example control tetrodotoxin (TTX) -sensitive currents recorded in transfected HEK293 cells in response to depolarizing voltage-clamp steps.
(B) Control peak current-voltage relation for hNaV1.7 (n = 4), expressed as a ratio of the maximal peak current.
(C) Average conductance expressed as a ratio of peak average conductance (G/Gmax) for control (black circles, n = 4), I1461T (open triangle,
n = 5), M1627K (open square, n = 6) and T1464I (open diamond, n = 5). Smooth curves are Boltzmann relations drawn with best-fit parameters
describing activation voltage-dependence for control and T1464I, with mid-points of215.9 and29.1 mV, respectively. Standard errors are plot-
ted for control and T1464I, calculated from normalized currents.
(D–F) Recordings of currents from mutants I1461T, T1464I, and M1627K, respectively, that reveal partial inactivation. All currents could be
completely blocked by superfusion of 250 nM TTX.
(G and H) Steady-state inactivation (hN) curves for I1461T and T1464I, respectively. Mutant I1461T and T1464I exhibit rightward-shifted and
incomplete inactivation, measured with 100 ms prepulses (plotted as open circles, I1461T mid-point = 230.8 mV, maximal inactivation =
54.7%, n = 3; T1464I mid-point = 250.7 mV, maximal inactivation = 63.5%, n = 6; best-fit values for Boltzmann relations).
(I) Control hN, (plotted as black circles, n = 3), measured using 60 ms duration prepulses. Smooth curve through inactivation data is a Boltzmann
relation, with a mid-point of260.1 mV and a slope-factor of221.9 mV. The hN curve for M1627K is shown (open circles) (mid-point of237.9 mV,
slope =217.0 mV, n = 5, 60 ms prepulse), and is significantly shifted to positive values in comparison with control data (between groups p < 0.001,
two-way ANOVA, Sigma-Stat).
Where possible, data are given as mean 6 SEM.and the Supplemental Data) while the transient current
evoked in the same protocol was spared. The dissocia-
tion constant (Kd) obtained from individual data sets is
32.7 6 8.2 mM (n = 4), assuming that complete block is
possible, a value within the range of therapeutic plasma
concentrations observed in patients (Breton et al.,
2005). Although these observations indicate that this
mutant channel is sensitive to carbamazepine in vitro
(as is the I1461T mutant, see the Supplemental Data),
the therapeutic effect in vivo may also depend on its ef-
fects on the other sodium channels, including Nav1.8,
expressed in the same sensory neurons. The negativeactivation potential of a PE mutant, I848T (Yang et al.,
2004) (Figure 4D), was unaffected by exposure to 100
mM carbamazepine, demonstrating the molecular basis
for the difference in drug effectiveness in PEPD and PE.
Discussion
We have identified eight SCN9A mutations in families
with PEPD. All are missense, indicating a gain-of-func-
tion or dominant-negative mechanism for the autosomal
dominant inheritance displayed in familial cases. PEPD
is the second inherited pain disorder to be shown to be
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771Figure 4. Carbamazepine Blocks Persistent Currents Generated by PEPD Mutant T1464I, But Does Not Affect the Activation Threshold of I848T
Erythermalgia Mutant
(A) Persistent current generated following partial inactivation of T1464I is blocked by carbamazepine, whereas the transient current is spared in
the voltage-clamp protocol.
(B) The effect of a range of drug concentrations on the hN curve (100 ms duration prepulses) for the same cell as in (A) with the minimum value of
h approaching zero as the drug concentration is increased. Carbamazepine appears to increase the maximal amount of inactivation in the mutant
in a concentration-dependent manner (control, black circles; 10 and 50 mM, open circles and open triangles, respectively). Similar results were
found in four other cells.
(C) The apparentKd for block of persistent current was estimated from the asymptote of the hN curve, without the drug, and in the presence of 10
and 50 mM carbamazepine (n = 4). Smooth curve is a rectangular hyperbola drawn according to best-fit parameters to the mean data, with an
apparent Kd of 34.3 mM maximal block of 100% (Kd estimated from individual data sets, 32.7 6 8.2 mM).
(D) Erythermalgia mutant I848T has a more negative activation threshold than normal. I848T (black circles, n = 7) half-maximal activation potential
is221.4 mV (best-fit Boltzmann curve, heavy line), shifted over 5 mV negative when compared with control curve (fine line, same as that shown in
Figure 3C). Exposure to 100 mM carbamazepine (open circles, n = 4) does not shift the mutant activation threshold to more positive values.attributable to mutations inSCN9A. Nine mutations have
recently been shown to be associated with PE (Dib-Hajj
et al., 2005; Drenth et al., 2005; Michiels et al., 2005;
Yang et al., 2004). In contrast to phenotypes associated
with mutations in SCN1A (Meisler and Kearney, 2005),
sporadic cases with haplo-insufficiency have not been
observed in these SCN9A-related disorders, and vari-
able phenotypic expression is limited within families,
suggesting that modifier genes are less important in
channelopathies of peripheral nerves than in those of
central neurons. Our results suggest that around two-
thirds of families with PEPD have mutations in SCN9A,
suggesting the existence of locus heterogeneity, as in
other sodium channelopathies (George, 2005).
Altered function of hNav1.7 in nociceptive and sympa-
thetic neurons is likely to underlie the pain and flushing
common to both PEPD and PE. However, there are
marked clinical differences between the phenotypes,
as well as differential responses to medication. PEPDis essentially a visceral pain condition, often unpro-
voked, with marked cranial nerve involvement, whereas
PE is a condition primarily affecting the extremities in
which the triggers, such as exercise and temperature
change, are well documented. To what extent can these
differences, including the responses to sodium channel
blockers, be accounted for by the functional effects
caused by the mutations studied? Three PE mutations
have been studied. Two, I848T and L858H (Yang et al.,
2004), cause a significant hyperpolarizing shift in activa-
tion, slow deactivation, and increased response to small
ramp depolarizations (Cummins et al., 2004). A third mu-
tation, F1449V, produces a smaller hyperpolarizing shift
in activation and a depolarizing shift in steady-state in-
activation, leading to a lowering of the threshold for sin-
gle action potentials and high-frequency firing in DRG
neurons (Dib-Hajj et al., 2005). These effects are likely
to reduce the activation threshold for sensory and noci-
ceptive neurons, causing the chronic hyperalgesia,
Neuron
772inflammation, and central sensitization associated with
activation through nonnoxious stimulation, e.g. walking.
In marked contrast to the functional effects of PE mu-
tations, the three PEPD mutants studied here display
marked deficits in sodium channel fast inactivation. Sim-
ilar effects on fast inactivation have been described for
muscle sodium channels in myotonia (Cannon, 2000;
Wu et al., 2005). In PEPD such inactivation deficits
may only become apparent after near-normal activation
and would promote prolonged action potentials and re-
petitive firing in response to provoking stimuli, such as
stretching and experiencing cold. In either case, it is
likely that the role of Nav1.7 as a ‘‘threshold channel’’
is a factor, with Nav1.8 probably contributing to the re-
generative current at the nerve ending (e.g., Strassman
and Raymond, 1999; Renganathan et al., 2001; Carr
et al., 2002).
Such allelic heterogeneity is not uncommon in the
channelopathies. There are several well-documented
examples of channels in which different mutational
mechanisms lead to clinically distinct phenotypes.
These include generalized epilepsy with febrile seizures
plus (GEFS+) and severe myoclonic epilepsy of infancy in
SCN1A; the skeletal muscle disorders, hyperkalaemic
periodic paralysis (HYPP) and myotonia, caused by mu-
tations inSCN4A; and the cardiac disorders long-QT and
Brugada syndromes, caused by mutations in SCN5A
(reviewed in detail in George, 2005). It is of interest to
note that GEFS+, long-QT, and HYPP, in a situation anal-
ogous to that of PEPD, are largely the result of gain-of-
function mutations leading to persistent sodium current.
That there are clear mechanistic differences between
PEPD and PE is supported by their differential re-
sponses to drug therapy. Oral mexiletine and topical
lidocaine, both local anesthetic/type 1b anti-arrhythmia
drugs, have been reported to give relief in PE (Legroux-
Crespel et al., 2003), whereas many PEPD patients re-
spond well to the anti-epilepsy drug carbamazepine.
Mexiletine is also effective in skeletal muscle myotonias
arising from mutations in hNav1.4 (Mohammadi et al.,
2005). It is noteworthy that certain myotonia mutations
(e.g., substitutions of R1448) respond well to the drug,
an effect ascribed to an increased probability of the
channel being in closed-state inactivation and/or en-
hanced recovery from fast inactivation (Mohammadi
et al., 2005). A similar effect on channel kinetics is seen
in the PE mutant F1449V, so the response to mexiletine
may be mutation-specific. Carbamazepine also blocks
sodium channels in a use-dependent manner and has
long been established as a treatment for neuropathic
pain (Backonja, 2002), but has little or no effect in PE
(Waxman and Dib-Hajj, 2005). This is consistent with
pain in PEPD being precipitated by persistent Na current
(because carbamazepine preferentially suppresses
persistent Na current, as demonstrated for two of the
mutants studied—see the Supplemental Data) in com-
parison with the pain in PE being caused by lowered
activation thresholds.
In summary, these observations establish the exis-
tence of allelic heterogeneity in a class of sodium chan-
nelopathy affecting peripheral neurons. PEPD and PE
are both inherited autosomal dominant inflammatory
pain conditions, but have entirely distinct phenotypes.
Our data demonstrate that these distinct phenotypesare the result of distinct repertoires of mutations lead-
ing to either lowered thresholds of activation (PE) or
defective inactivation (PEPD) These data further empha-
size the critical role of Nav1.7 in human inflammatory
pain and explain the differential drug sensitivity of PEPD
and PE.
Experimental Procedures
Subjects
This study was approved by the joint UCL/UCLH committees on the
ethics of human research. Informed consent was obtained from all
participants or their parents. Twelve families and two sporadic
cases (family 8 and 9) with PEPD were ascertained using the diag-
nostic criteria outlined below.
Diagnostic Criteria
PEPD is a rare, autosomal dominant paroxysmal disorder of pain and
autonomic dysfunction that presents with four types of painful
episode: (1) birth crisis, when babies are born red and stiff; (2) rectal
crisis, which is triggered by defecation in infants and young children
and by a variety of emotional factors in older children and adults; (3)
ocular crisis, which may be provoked, but is more usually spontane-
ous, and (4) mandibular crisis, which is often triggered by eating and
yawning. The distinctive features of this condition are paroxysmal
episodes of burning pain in the rectal, ocular, and mandibular areas,
accompanied by the autonomic manifestations such as skin flushing,
reflex asystolic syncopal events, lacrimation, and rhinorrhoea. In be-
tween episodes, physical examination is normal, and investigations
such as imaging or tissue biopsy are normal. Diagnosis therefore
relies on the history and either direct observation or video of the ep-
isodes. The former is, of course, more helpful in adults and the latter
in infants and children.
Family 1 was originally referred with an erroneous diagnosis of
hyperekplexia. Other families were ascertained from previous publi-
cations (Mann and Cree, 1972; Schubert and Cracco, 1992) or by
direct contact from those managing affected children. Family 7 is
a recently ascertained large pedigree from Berkshire, UK and was
selected for linkage analysis. Detailed clinical documentation of
this family will be published elsewhere. In all cases, DNA was ex-
tracted from venous blood or buccal swabs from patients and unaf-
fected family members using standard methods.
Genotyping and Linkage Analysis
Primers flanking a total of 455 polymorphic loci primarily identified
from the Ge´ne´thon map spanning the human genome were used in
the genome search in family 7. Primers were obtained from MRC
HGMP Resource Centre, Research Genetics, MWG Biotech, and In-
vitrogen. These microsatellites were genotyped using a fluorescent-
based semi-automated method on automated DNA sequencing
machines (ABI 373A, ABI 3100).
Mutation Screening
Primers were designed for the mutation screen of SCN9A from the
genomic sequence obtained from the Human Genome Browser
(http://genome.ucsc.edu/). Intronic primers were designed to flank
each exon (or groups of exons if separated by small introns). Exons
from each of the eight probands and appropriate controls were am-
plified and sequenced on an automated DNA sequencer (ABI 373A
or ABI 3100) and the sequences aligned and compared using
Sequence Navigator v1.0.1.
Cloning and Mutagenesis
A full-length version of the human Nav1.7 cDNA was cloned into
a modified version of the expression vector pcDNA3 (Klugbauer
et al., 1995). For functional analysis, three mutated constructs were
made (I1461T, T1464I, M1627K). These single base substitutions
were introduced into this wild-type clone by PCR-based site-
directed mutagenesis using the QuikChange II XL kit (Stratagene,
La Jolla, CA). Correct introduction of these substitutions was
confirmed by complete sequencing of the inserts.
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HEK293 cells were grown in sparse culture in 35 mm diameter Petri
dishes. Transfections were carried out in serum-free medium by in-
cubating with pcDNA3 incorporating Nav1.7 cDNA and mutant DNA
0.8–1.3 mg 3 ml lipofectamine 2000, 0.2 mg pBS500 for 2 hr at 37C.
The medium was then replaced with normal culture medium incorpo-
rating 5% serum. Recordings were made from 1–2 days later.
Solutions and Electrophysiology
Conventional voltage-clamp recordings in the whole-cell patch-
clamp configuration were made from HEK293 cells 1–2 days follow-
ing transfection, using an Axopatch 200B amplifier (Axon Instru-
ments, Union City, California, USA) driven from a PC generating pulse
protocols (Pclamp 9, Axon Instruments). The extracellular solution
contained the following: 140 mM NaCl, 10 mM Tetraethylammonium
Cl, 10 mM HEPES, 2.1 mM CaCl2, 2.12 mM MgCl2, 0.5 mM 4-Amino-
pyridine, 7.5 mM KCl, and 0.1 mM CdCl. The intracellular solution
contained the following: 130 mM CsCl, 13 mM CsF, 3 mM EGTA
(Na), 10 mM Tetraethylammonium Cl, 10 mM HEPES, 1.21 mM
CaCl2, 3 mM ATP(Mg), and 500 mM GTP (Li). The external and internal
solutions were buffered to pH 7.2–7.3 with the addition of NaOH and
CsOH, respectively. Electrodes were made from thin-walled glass
capillaries (Harvard Apparatus, Edenbridge, Kent, UK), with initial
resistances of 1–2 MUwhen filled with recording solution. During re-
cording, series-resistance compensation was always used and set to
70% or higher. Families of sodium currents were recorded in re-
sponse to a series of incrementing depolarizing voltage-clamp steps
from a holding potential of290 mV. Steady-state inactivation proto-
cols comprised an incrementally depolarizing prepulse, 60 or 100 ms
in duration, followed immediately by a depolarizing step to +10 mV.
Records were usually filtered at 5 KHz (4-pole Bessel) and sampled
at 20 or 10 KHz. Current traces were generated by averaging three
or more records. Leak subtraction was achieved using a P/N proto-
col, where five reverse polarity clamp-steps were used to produce
the leakage record. TTX was applied to ascertain that the currents
were indeed TTX-s sodium currents. The HEK293 cells failed to gen-
erate TTX-s currents unless they were transfected with an hNaV1.7
clone. Because HEK293 cells can generate nonlinear leakage cur-
rents, records of membrane currents were made both before and
after the application of TTX, and the TTX-sensitive component was
isolated by off-line digital subtraction. TTX (250 nM) and carbamaze-
pine (up to 200 mM) were applied by local superfusion. Carbamaze-
pine was made up as a stock solution of 50 mM or 200 mM in
DMSO. Recordings were made at room temperature.
Data Analysis
Peak currents were converted to conductances, assuming that the
sodium equilibrium potential (ENa) was +70 mV, allowing activation
curves to be plotted. Boltzmann relations were drawn according to
best-fit parameters (Sigma-Stat) for activation curves andhNcurves.
The maximal block in the presence of carbamazepine was derived
from the asymptote of the hN curve or (as in the Supplemental
Data) by measuring the residual current amplitude at 0 mV. Concen-
tration block data for carbamazepine was described as a rectangu-
lar-hyperbola (Langmuir isotherm), assuming that 100% block was
achievable, from which the apparent Kd for block could be derived.
Supplemental Data
The Supplemental Data for this article includes six figures and can
be found online at http://www.neuron.org/cgi/content/full/52/5/
767/DC1/.
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